Replies to post #273 on Gamida Cell Ltd (GMDAQ)

[midastouch017]

Hi top123. i womder if you read this:

Omidubicel, also known as NiCord, has been developed using the company's proprietary nicotinamide (NAM) cell-expansion platform technology, which is used to increase both the number and efficacy of any type of donor cells. In addition to being a superior treatment option over the currently available umbilical cord blood transplant, omidubicel can also offer an off-the-shelf treatment option to around 5,200 blood cancer patients who are eligible for a bone marrow transplant, yet unable to undergo it due to low availability of matching donors. Within three years from its launch, the company expects omidubicel to treat around 2,000 U.S. patients annually and capture 20% share of the bone marrow transplantation market, which is estimated to be worth $13.9 billion by 2026. #msg-161885562

If that article numbers are correct, what SP numbers are we looking at

I would estimate company m/c of $1.5-2billion, sp should be in
the area of ~$30-35